E
KRSA

Ergoteles’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Ergoteles’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-686
Closed -$375K – 1305
2021
Q2 		$375K Buy
+686
New +$43K 0.01% 952

Other funds holding KRSA

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ergoteles's KRSA Position: Q3 2021 in Review

Ergoteles sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q3 2021, closing a stake of 686 shares — an estimated $375K sold.

Ergoteles first reported a position in KRSA in Q2 2021 and held it in 1 quarter. The position peaked at $375K in Q2 2021. 58 funds tracked by Wall St. Rank hold KRSA as of Q3 2021.

  • Ergoteles reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Ergoteles sold 686 Korsana Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $375K.
  • Ergoteles first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Ergoteles's Korsana Biosciences, Inc. Common Stock position peaked at $375K in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.